Scholar Rock Q1 net loss $74.7M; BLA priority review set for Sept 22, 2025; cash to 2027

Scholar Rock Holding Corp

2025-Q1 EPS reported -$0.67

Net loss $74.7M ($0.67 per share) vs $56.9M in Q1 2024; no revenue.
Cash, equivalents, securities $364.4M as of March 31, 2025; expected to fund into 2027.
FDA accepted BLA for apitegromab with priority review; PDUFA date Sept 22, 2025.
Topline results from Phase 2 EMBRAZE obesity trial expected June 2025.
Leadership: David Hallal CEO; Akshay Vaishnaw President R&D; Keith Woods COO; Vikas Sinha CFO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.